How Can We Help?
Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.[1][2]
It was being developed as an anti-cancer therapy by Antisoma.[3]
As of 2008, it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).[4] In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.[citation needed]
See also
References
- ^ Allen SL, Lundberg AS (July 2011). "Amonafide: a potential role in treating acute myeloid leukemia". Expert Opinion on Investigational Drugs. 20 (7): 995–1003. doi:10.1517/13543784.2011.585756. PMID 21591994. S2CID 10999582.
- ^ Freeman CL, Swords R, Giles FJ (February 2012). "Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?". Expert Review of Hematology. 5 (1): 17–26. doi:10.1586/ehm.11.68. PMID 22272701. S2CID 26740617.
- ^ "Antisoma's Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial". Genetic Engineering & Biotechnology News. 29 March 2010. Archived from the original on 1 April 2010.
- ^ Clinical trial number NCT00715637 for "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study" at ClinicalTrials.gov
External links
- Amonafide entry in the public domain NCI Dictionary of Cancer Terms
- Clinical trials of amonafide at ClinicalTrials.gov
This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.
Recent Comments